Douglas B. Johnson

3.3k total citations · 1 hit paper
10 papers, 1.5k citations indexed

About

Douglas B. Johnson is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Douglas B. Johnson has authored 10 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 3 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Douglas B. Johnson's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (4 papers) and Immune Cell Function and Interaction (3 papers). Douglas B. Johnson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (4 papers) and Immune Cell Function and Interaction (3 papers). Douglas B. Johnson collaborates with scholars based in United States, France and Canada. Douglas B. Johnson's co-authors include Joe‐Elie Salem, Javid J. Moslehi, Bénédicte Lebrun‐Vignes, Marc P. Bonaca, Melissa Moey, Jean‐Philippe Spano, Ali Manouchehri, Justin M. Balko, Dan M. Roden and Lisa Bastarache and has published in prestigious journals such as Circulation, Circulation Research and The Lancet Oncology.

In The Last Decade

Douglas B. Johnson

10 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

2018 836 citations Joe‐Elie Salem, Ali Manouchehri et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Douglas B. Johnson

Since Specialization

Citations

This map shows the geographic impact of Douglas B. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas B. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas B. Johnson more than expected).

Fields of papers citing papers by Douglas B. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas B. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas B. Johnson. The network helps show where Douglas B. Johnson may publish in the future.

Co-authorship network of co-authors of Douglas B. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas B. Johnson. A scholar is included among the top collaborators of Douglas B. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas B. Johnson. Douglas B. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis 2025 ·Nature Cardiovascular Research ·(unknown), Douglas B. Johnson, Javid J. Moslehi, Justin M. Balko	1
2	Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade 2025 ·OncoImmunology ·(unknown), Rebecca Irlmeier, Xue Bai, (unknown), Fei Ye, (unknown), Aleigha Lawless, (unknown), Ryan J. Sullivan, Douglas B. Johnson	1
3	Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), Douglas B. Johnson	18
4	Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review 2021 ·European Journal of Cancer ·Lee S. Nguyen, Sofia Ortuno, Bénédicte Lebrun‐Vignes, Douglas B. Johnson, Javid J. Moslehi, Alexandre Hertig, Joe‐Elie Salem	47
5	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies 2021 ·Circulation Research ·Alan H. Baik, Olalekan O. Oluwole, Douglas B. Johnson, Nina Shah, Joe‐Elie Salem, Katy K. Tsai, Javid J. Moslehi	80
6	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities 2020 ·Autoimmunity Reviews ·Yves Allenbach, C. Anquetil, Ali Manouchehri, Olivier Benvéniste, Olivier Lambotte, Bénédicte Lebrun‐Vignes, Jean‐Philippe Spano, Stéphane Éderhy, David Klatzmann, Michèlle Rosenzwajg, Bruno Fautrel, Jacquès Cadranel, Douglas B. Johnson, Javid J. Moslehi, Joe‐Elie Salem	96
7	Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis 2020 ·The Oncologist ·Virginie Grouthier, Bénédicte Lebrun‐Vignes, Melissa Moey, Douglas B. Johnson, Javid J. Moslehi, Joe‐Elie Salem, Anne Bachelot	88
8	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance 2020 ·The Annual Review of Pharmacology and Toxicology ·Arthur Géraud, Paul Gougis, Aurore Vozy, C. Anquetil, Yves Allenbach, Emanuela Romano, Elisa Funck‐Brentano, Javid J. Moslehi, Douglas B. Johnson, Joe‐Elie Salem	60
9	Myocarditis in the Setting of Cancer Therapeutics 2019 ·Circulation ·Marc P. Bonaca, Benjamin A. Olenchock, Joe‐Elie Salem, Stephen Wiviott, Stéphane Éderhy, Ariel Cohen, Garrick C. Stewart, Toni K. Choueiri, Marcelo F. Di Carli, Yves Allenbach, Dharam J. Kumbhani, Lucie Heinzerling, Laleh Amiri‐Kordestani, Alexander R Lyon, Paaladinesh Thavendiranathan, Robert F. Padera, Andrew H. Lichtman, Peter P. Liu, Douglas B. Johnson, Javid J. Moslehi	288
10	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study breakdown → 2018 ·The Lancet Oncology ·Joe‐Elie Salem, Ali Manouchehri, Melissa Moey, Bénédicte Lebrun‐Vignes, Lisa Bastarache, Alexandre Pariente, Aurélien Gobert, Jean‐Philippe Spano, Justin M. Balko, Marc P. Bonaca, Dan M. Roden, Douglas B. Johnson, Javid J. Moslehi	836

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact